Novartis’ new multiple myeloma is treatment too risky to be approved, a group of FDA advisers voted, dealing a blow to the drugmaker and its hopes of launching the cancer drug next year.

…read more

Source: FDA advisers spurn Novartis’ blood cancer drug, putting approval in doubt


0 No comments